ReachRxResearch
Home
Research
Sign Up
Discontinuing Surveillance of Low‐Risk Branch‐Duct Intraductal Papillary Mucinous Neoplasms in Routine Practice: An External Application of the “Trivial” Criteria and the Resources it Would Release in Fourteen Health Systems
Back to Research Hub
  1. Home
  2. Research Hub
  3. Discontinuing Surveillance of Low‐Risk B…

Discontinuing Surveillance of Low‐Risk Branch‐Duct Intraductal Papillary Mucinous Neoplasms in Routine Practice: An External Application of the “Trivial” Criteria and the Resources it Would Release in Fourteen Health Systems

United European Gastroenterology Journal·October 9Open Access
Gastroenterology & HepatologyLimited evidenceBranch-Duct Intraductal Papillary Mucinous NeoplasmProspective Cohort StudySurveillance ImagingOlder Adult

Summary

View source

What was studied

In a single-center cohort of 392 patients with low-risk branch-duct IPMNs (BD-IPMNs) followed for a median of 67 months (2375 person-years total), the study tested published 'trivial' criteria for stopping surveillance after 5 years of stability — specifically, age ≥75 with cyst <30 mm, or age ≥65 with cyst ≤15 mm — measuring how many high-grade lesions would be missed and what resources would be released across 14 health systems.

Key findings

Applying the discontinuation criteria would have discharged 101 patients (25.8%) with no high-grade dysplasia or invasive carcinoma missed, releasing 298 person-years and €79,316 per 1,000 patients entering surveillance; the upper 95% bound of the undetected high-grade lesion rate was 0.84 per 100 person-years, and the same rule released €42,000–€170,000 per 1,000 patients depending on which health system's tariffs were used.

Study limitations

Single-center retrospective cohort (n=101 discharged, 298 person-years released) is too small to exclude a clinically relevant rate of missed high-grade lesions (upper 95% bound 0.84/100 person-years); only 67% of protocol-intended cross-sectional exams were performed, potentially reducing sensitivity for detecting progression; cost analysis takes the payer perspective only, omitting patient time, travel, psychological burden, and outpatient visits.

Clinical implications

Stopping BD-IPMN surveillance after 5 stable years in patients aged ≥75 (cyst <30 mm) or ≥65 (cyst ≤15 mm) appeared safe in this external cohort, but cannot yet be considered proven — the economic benefit is modest and highly dependent on local imaging costs and actual surveillance delivery rates, so institutions should recalculate savings locally before citing published figures.

Caveats

  • Economic estimates are not transferable across health systems: the identical surveillance pattern cost €79/person-year in Japan vs €318 in Sweden, producing a fourfold range in projected savings — local recalculation is essential before applying these figures
  • Only 67% of protocol-intended cross-sectional imaging was actually delivered (0.64 vs 0.95 exams/person-year), reflecting real-world MRI capacity constraints that may have reduced event detection and inflated the apparent safety of early discharge
  • The cohort contributed only 298 person-years after applying the discontinuation rule, leaving the upper 95% credible bound for missed high-grade lesions at 0.84 per 100 person-years — the study is compatible with safety but cannot establish it

Related Questions

Explore related topics

When is it safe to stop pancreatic cyst surveillance in older patients?How do branch-duct IPMN guidelines differ on stopping surveillance after 5 years of stability?What are the costs of long-term pancreatic cyst MRI surveillance across different health systems?

Publication Details

Year
2026
Journal
United European Gastroenterology Journal
Sample Size
n=392
Source
View article
Keep scrolling
More content below.
Up Next